DJIA 17,586.97 -11.23 -0.06%
NASDAQ 5,112.34 -3.04 -0.06%
S&P 500 2,096.28 -1.76 -0.08%
market minute promo

ImmunoGen (NASDAQ: IMGN)

16.35 -0.28 (-1.68%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

IMGN $16.35 -1.68%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $16.72
Previous Close $16.63
Daily Range $16.34 - $16.76
52-Week Range $5.34 - $19.43
Market Cap $1.4B
P/E Ratio -25.58
Dividend (Yield) $0.00 (0.0%)
Volume 483,677
Average Daily Volume 1,255,697
Current FY EPS -$1.13




Drug Makers

ImmunoGen (IMGN) Description

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website:

News & Commentary

ImmunoGen: Back to a Development-Stage Biotech

With the biotech no longer collecting Kadcyla royalties, the pipeline becomes the focus of the release of quarterly earnings.

Why Cantor's Mara Goldstein Just Downgraded ImmunoGen

Benzinga's Top Downgrades

Analysts' Actions -- Bunge, Coach, Realogy and More

ImmunoGen's (IMGN) CEO Dan Junius on Q4 2015 Results - Earnings Call Transcript

ImmunoGen (IMGN) Q2 2015 Results - Earnings Call Webcast

ImmunoGen Is Climbing Higher... Again

ImmunoGen's shares continue to gain ground in the wake of early-stage trial results for its ovarian cancer drug.

ImmunoGen, Inc.'s Shares Jumped Another 15% Today

Immunogen shares continue to advance on the heels of positive trial data last month.

Monday's ETF Movers: XBI, GDX

10 Best Biotech Stocks in the NASDAQ

See More IMGN News...

IMGN's Top Competitors

IMGN $16.35 (-1.68%)
Current stock: IMGN
AMGN $174.79 (-0.46%)
Current stock: AMGN
GILD $118.75 (-0.71%)
Current stock: GILD
BIIB $329.97 (1.72%)
Current stock: BIIB